[Respiratory syncytial virus infections and ribavirin: the controversy continues].
Aujard
Y
Y
D000998:Antiviral Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D005602:France; D006801:Humans; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000191:economics; D012254:Ribavirin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D000998:Antiviral Agents; D012254:Ribavirin